Upgrade to SI Premium - Free Trial

Merck (MRK) Announces EMA Adopts Positive Opinion for its KEYTRUDA for Six-Week Dosing Schedule Across All Current Monotherapy Indications

March 4, 2019 6:46 AM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles